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Purpose: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone
metastases (BMs) from RCC since bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC).
Materials and methods: Data of patients with BMs from RCC were retrospectively collected. Age, sex,
ECOG-Performance Status (PS), MSKCC group, tumor histology, presence of concomitant metastases to other
sites, time from nephrectomy to bone metastases (TTBM, classified into three groups: <1 year, between 1 and 5 years
and >5 years) and time from BMs to skeletal-related event (SRE) were included in the Cox analysis to investigate
their prognostic relevance.
Results: 470 patients were enrolled in this analysis. In 19 patients (4%),bone was the only metastatic site; 277 patients
had concomitant metastases in other sites. Median time to BMs was 16 months (range 0 − 44y) with Median OS of
17 months. Number of metastatic sites (including bone, p = 0.01), concomitant metastases, high Fuhrman grade
(p < 0.001) and non-clear cell histology (p = 0.013) were significantly associated with poor prognosis. Patients with
TTBM >5 years had longer OS (22 months) compared to patients with TTBM <1 year (13 months) or between 1
and 5 years (19 months) from nephrectomy (p < 0.001), no difference was found between these two last groups
(p = 0.18). At multivariate analysis, ECOG-PS, MSKCC group and concomitant lung or lymph node metastases were
independent predictors of OS in patients with BMs.
Conclusions: Our study suggest that age, ECOG-PS, histology, MSKCC score, TTBM and the presence of concomitant
metastases should be considered in order to optimize the management of RCC patients with BMs.
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Renal cell carcinoma (RCC) accounts for approximately
5% of epithelial cancers worldwide with clear cell RCC
representing 85% of these tumors [1]. Almost one third
of patients present with synchronous metastatic disease
and another 20% experience recurrence or develop
metastatic RCC (mRCC) after nephrectomy [2,3].
The introduction of tyrosine kinase (TKIs) and mTOR
inhibitors has completely revolutionized the therapeutic
scenario of mRCC, suddenly replacing immunotherapy
as the standard of care for these patients. Seven agents
have been approved by the US Food and Drug Adminis-
tration (FDA), starting from sorafenib in 2005, followed
by sunitinib, bevacizumab plus interferon, everolimus,
temsirolimus, pazopanib and axitinib. However, new
clinical and molecular predictive and prognostic bio-
markers are dramatically required in order to optimize
the use of novel effective agents for mRCC.
Bone metastases (BMs) occurs in almost 35% of pa-
tients with advanced RCC [4]. Although the manage-
ment of patients with BMs has been markedly improved
by the introduction of bone-directed targeted therapies,Figure 1 Bone metastases occurred at time of clear cell RCC diagnositheir prognosis is still dismal, with a mean survival of
12 months [4-6]. Skeletal involvement is commonly an
aggressive, lytic process which causes substantial mor-
bidity through skeletal related events (SREs), defined as
a pathological fracture, surgical intervention, require-
ment for palliative radiotherapy to bone, spinal cord
compression or hypercalcemia. Almost 70% of RCC pa-
tients with BMs experience at least one SRE [7].
The probability to develop BMs in RCC patients paral-
lels with increased survival related to the introduction of
biological therapies (Figure 1). Several studies suggest
that the presence of BMs is associated with poor prog-
nosis [8,9]. BMs are usually related to a more aggressive
subtype of disease as suggested by the higher percentage
of patients with metastases or Fuhrman grade 4 at the
initial diagnosis, the shorter median time between neph-
rectomy and diagnosis of metastatic disease and the
greater number of metastatic sites at the diagnosis [10].
However, long survival in patients with BMs from RCC
is not a rare event. This may be partially explained by
data on tumor biological heterogeneity [11,12], although
other factors may affect the natural history of BMs ins (A) and 12 years after radical nephrectomy (B).
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the presence of existing prognostic factors in a large
cohort of patients with BMs from RCC.
Patients and methods
Data were extracted from the databases of 19 Italian
centers involved in the treatment of patients with mRCC.
Inclusion criteria were: histologic diagnosis of RCC,
clinical diagnosis of BMs, regularly conducted follow-up
of the disease, minimum uneventful follow-up of 1 year
after diagnosis of metastasis or alternatively known
death due to the disease. Pts were excluded from the
analysis if they had missing information about sites of
metastasis or time to bone metastasis (TTBM).
Patients characteristics and clinic-pathological variables
considered in this study were: gender, age, eastern co-
operative oncology group performance status (ECOG-
PS), tumor histology, clinical stage at time of surgery,
time from surgery to diagnosis of BMs, MSKCC risk-
group, type and number of sites of metastasis, time
from BM to development of further metastatic sites and
presence/type of SREs. Since we gathered data from
RCC patients treated from 2001 onwards, we were not
able to categorize all of them according to the novel
IMDC (or Heng’s) prognostic classification.
BMs were assessed with bone scan and confirmed by
contrast-enhanced CT, while other metastatic sites were
defined either with total body contrast-enhanced CT or
MRI.
Cancer-specific survival was computed both from any
site-metastasis and from BM to the event (death) and
both measurements were considered as outcome
measures.
Continuous covariates (age, TTBM) were grouped into
discrete ordinal categories. Age was divided in two or-
dinal groups (<65 years and ≥65 years). Correlation
between continuous variables was assessed by means of
Pearson product-limit correlation coefficient [12]. As
outcome variables, the overall survival (OS) from the
diagnosis of BMs was analyzed.
Patients were grouped according to TTBM: Group A
(<1 year), Group B (between 1 and 5 years) and Group
C (>5 years). The choice of these cut-offs was related to
the reported data on the prognostic effects of early
(within 1 year) or late (>5 years) time to metastasis on
the outcome of RCC patients [13-16].
Survival analysis was conducted via the Kaplan-Meier
method and Mantel-Haenszel log-rank test was employed
to compare survival among groups. A Cox-regression
model was applied to the data with a univariate and multi-
variate approach. The assumption of proportionality of
hazards was assessed using the Therneau and Grambsch
test of the Schönefeld residuals [17]. Variables not fitting
at univariate regression analysis were excluded for themultivariate model. No-multicollinearity of the grouped
co-variates was also checked. Significance level in the uni-
variate model for inclusion in the multivariate final model
was more liberally set at a 0.2 level, according to Hosmer
et al. [17]. All other significance levels were set at a 0.05
value. Statistical analysis was conducted with R –Software
version 3.0.1 (The R Company – Vienna –Austria).
Results
We retrospectively collected clinical data of 511 patients
with RCC BMs from 19 Italian Institutions followed be-
tween January 2001 and April 2014. Of 470 patients
were available for this analysis (41 were excluded due to
lack of data on BMs or follow-up). Median age was
65 years (range 30 to 92 years). Three hundred and
thirty-five patients (71%) were males; 398 (85%) had
clear cell RCC, whereas 72 (15%) presented with other
histologies (5% papillary, 1% chromophobe, 9% other).
The complete list of patient characteristics is shown in
Table 1.
Median number of bone metastases was 2. Median
number of SREs was 1 (range 0 to 6 events). The median
TTBM was 16 months (95% CI 0 – 64). Median time to
first SRE was 2 months (95% CI 0 – 4) from BM diagno-
sis. Median OS was 17 months (95% CI 14 to 19).
Prognostic categories using MSKCC criteria were good
in 198 pts (42%), intermediate in 219 (47%) and poor in
53 (11%). The median OS was 22 (95% CI 20 to 32), 18
(95% CI 14 to 22) and 7 months (95% CI 6 to 10) in
patients with good, intermediate and poor prognosis,
respectively (p < 0.001).
A significantly higher mortality both from the diagno-
sis of mRCC and BMs was observed in patients develop-
ing metastases < 65y compared to ≥ 65 (median OS:
15 months (95% CI 13 to 20) vs 21 months (95% CI 18
to 24), p = 0.038 (Figure 2A). No differences in OS were
observed based on sex (p = 0.31).
Clear-cell histology was correlated with a longer survival
as compared with other histologic types (18 months
[95% CI 15 to 20] vs 12 months [95% CI 8 to 18],
p = 0.014 Figure 2B), but this observation is someway
hampered by the small number of patients with non-
clear cell histologies and the heterogeneous natural
history of the different histotypes. Also ECOG-PS at time
of diagnosis of metastatic disease was related to patients’
survival at univariate analysis (log-rank p < 0.001; HR:
1.22, 95% CI 1.05-1.40, p = 0.007).
The number of BMs was associated neither with the
number of SREs (p = 0.096) nor with OS (HR: 1.17, 95% CI
0.92-1.43, p = 0.21). No significant differences in terms
of OS were found when comparing patients presenting
with visceral metastases as first metastatic sites with
those with BMs as first metastatic site (HR: 1.18, 95% CI
0.89 to 1.54, p = 0.25).
Table 1 Patient demographics and disease characteristics
Patients, n (%) (N = 470)
Median age, y (range) 65 (30–92)
Sex
Male 335 (71)
Female 135 (29)
Tumor histology
Clear cell 398 (85)
Papillary 25 (5)
Chromophobe 5 (1)
Other 42 (9)
ECOG-Performance Status (PS) ≥2 60 (13)
Time to distant metastases (TTBM)
Group A (<1 year) 229 (49)
Group B (between 1 and 5 years) 107 (23)
Group C (>5 years) 134 (28)
MSKCC criteria
Good 198 (42)
Intermediate 219 (47)
Poor 53 (11)
Median number of bone metastases 2
Median number of SREs (range) 2 (1–6)
Sites of concomitant metastases
Lung 276 (59)
Lymph node 205 (44)
Liver 78 (17)
Brain 30 (6)
Adrenal gland 14 (3)
Treatment after onset of bone metastases 190 (41)
Sunitinib 61(12)
Sorefnib 4 (1)
Pazopanib 24 (5)
mTor inhibitors 191 (41)
Other treatments or no treatemnt
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comitant visceral metastases in patients with BMs. Two-
hundred seventy-six patients (59%) had concomitant lung
metastases, 205 (44%, with 28% retroperitoneal, 12% medi-
astinal and 4% to other sites) had metastases to lymph
nodes and 78 (17%) had liver metastases (Figure 3). Inter-
estingly, the number and site of concomitant metastases
was significantly associated with OS (p = 0.016) in our
population. The presence of concomitant lung (p = 0.012),
liver (p = 0.005), or lymph-node (p = 0.014) metastases was
significantly correlated with OS at univariate analysis,
while no correlation was shown for brain (p = 0.65) or
adrenal metastases (p = 0.374) (Table 2).At multivariate analysis, MSKCC risk group (p < 0.001),
ECOG-PS (p < 0.001), lymph-node (p = 0.03) and lung
(p = 0.009) metastases were independent prognostic
factors for OS (Table 2).
Patients were grouped according to TTBM: Group
A (<1 year, 229 patients), Group B (between 1 and
5 years, 107 patients) and Group C (>5 years, 134
patients). The number of metastatic sites was statisti-
cally different in the three groups, with a median of
1 site in Group A, 2 In Group B and 2 in Group C
(p = 0.001). TTBM was inversely correlated with MSKCC
risk group (testing for difference between groups with
non-homogeneous variances, Mann–Whitney U = 97,
p < 0.001, Kendal tau = −0.40, p < 0.001). Indeed, pa-
tients with longer TTBM presented more frequently
good risk features.
A significant difference was found for the distribution
of lung metastases (p < 0.001, Figure 3), with a higher in-
cidence in Group B compared to the other groups. No
significant differences were found for the incidence of
lymph-node (p = 0.20), liver (p = 0.24), adrenal, brain me-
tastases (p = 0.15) or local recurrence (p = 0.75).
As regard to OS, no significant difference was found
between Group A and B (13 months [95% CI 12 to 15]
vs 19 months [95% CI 12 to 26], p = 0.36), while signifi-
cant differences were found when comparing Group A
with Group C (13 months [95% CI 12 to 15] vs 22 months
[95% CI 20 to 33] p < 0.001) and Group B with Group C
(19 months [95% CI 12 to 26] vs 22 months [95% CI 20
to 33] p < 0.001) (Figure 4).
Finally, we identified three risk categories: the favor-
able risk group (Risk Score = 0–1 of previous confirmed
three prognostic factors, median OS = 21 months), the
intermediate risk group (Risk Score = 2, median OS =
12 months) and the poor risk group (Risk Score = 3,
median OS = 6 months) (p < 0.001, HR 1.91, 95% CI:
1.56-2.34, Figure 5).
Discussion
BMs are common in patients with mRCC, but the mech-
anism by which this tumor preferentially metastasize to
bone is poorly understood. The development of BMs is a
multifactorial process that requires a series of interac-
tions between invading tumor cells and the bone micro-
environment [18-20] and is sustained by the release of
factors, such as transforming growth factor-β (TGF-β),
bone morphogenetic proteins (BMPs) and bone sialopro-
tein (BSP), due to tumor-induced activity of osteoclasts
[11,21,22]. Satcher and colleagues suggested a crucial
role for cadherin-11 in the homing/retention of RCC
cells to bone and their subsequent proliferation. By using
an in vivo metastasis model of RCC, they revealed that
the expression of cadherin-11 was enhanced in in BM-
derived 786-O cells, and the knockdown of Cadherin-11
Figure 2 Overall Survival (OS) from the diagnosis of bone metastases (BMs) based on age (2A) and histology (2B).
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expression of several factors, including homing receptor
CXCR4, HIF-1α, VEGF, IL-6 and RANKL did not differ be-
tween cells metastasizing to bone or other organs [23].
Furthermore, Joeckel et al. showed that elevated
extracellular calcium levels are associated with increased
activity of AKT, PLCγ-1, p38α and JNK, with consequentlyFigure 3 Distribution of sites of concomitant distant metastases in paenhanced migration and proliferation of bone metastasiz-
ing RCC cells. This process was blocked by the use of
calcium-sensing receptor (CaSR) inhibitor NPS 2143, thus
suggesting a predictive role of CaSR and its pathway for
RCC bone metastases [24].
Recent evidences suggest that BMs have a negative im-
pact on clinical outcomes in patients with mRCC, eventients with bone metastases (BMs).
Table 2 Univariate and multivariable analysis of predictors of OS from the diagnosis of bone metastases (BMs) in
patients with RCC
UVA* MVA**
HR 95% CI P HR 95% CI P
Age (<65 vs ≥65) 0.8 0.64-0.99 0.04 0.83 0.65-1.07 0.15
Gender (M vs F) 0.84 0.68-1.04 0.31
Histology (CC vs NCC) 1.45 1.08-1.95 0.013 1.23 0.83-1.81 0.31
MSKCC group 1.94 1.64-2.29 <0.001 1.82 1.50-2.20 <0.001
ECOG-PS 1.44 1.26-1.64 <0.001 1.40 1.19-1.66 <0.001
Time from diagnosis of primary disease (<1 y - 1-5y - >5 y) 0.72 0.64-0.81 <0.001 1.00 0.83-1.21 0.97
Number of bone metastases (single- vs multiple sites) 1.15 0.92-1.43 0.21
Number of other sites of metastasis 1.17 1.04-1.32 0.011 1.06 0.78-1.44 0.70
Other sites of metastasis
Local recurrence 1.05 0.76-1.46 0.78
Lung 1.19 0.96-1.48 0.012 1.41 1.09-1.84 0.009
Liver 1.43 1.11-1.84 0.005 1.2 0.87-1.66 0.26
Lymph-nodes 1.30 1.06-1.59 0.014 1.30 1.02-1.67 0.03
Adrenals 0.77 0.43-1.37 0.374
Brain 0.91 0.62-1.35 0.65
Other sites 0.60 0.37-0.97 0.04 0.59 0.32-1.09 0.09
HR and significance levels of significant variables are given as computed after removal of non-significant covariates. *UVA: Univariate analysis. **MVA:
Multivariate analysis.
cc = clear cell; ECOG-PS = Eastern Cooperative Oncology Group Performance Status; F = female; bold p value represents independent prognostic factor for OS.
M =male; MSKCC =Memorial Sloan Kettering Cancer Center.
Figure 4 Overall survival (OS) from the diagnosis of bone metastases (BMs) based on the time of bone recurrence from nephrectomy (TTBM).
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Figure 5 Risk Stratification Model in patients with bone metastases (BMs) based on the presence of significant prognostic factors
resulted from multivariate analysis (MSKCC risk, ECOG-PS, lymph-node and/or lung metastases).
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[8,9]. Some authors suggest that bone metastases may
have also a predictive significance, particularly with anti-
VEGF-targeted therapy [18,25-27], but this observation re-
quires further investigations and a formal validation. In
addition, the role of bisphosphonates in association with
targeted therapy in these patients is still controversial
[26,28,29].
Santini et al. screened the records of more than 1800
patients who died from RCC, finding 398 patients (22%)
with BMs [7]. They showed that the majority of patients
with BMs at the time of RCC diagnosis were classified
as poor risk according to MSKCC criteria, while most of
good and intermediate risk patients developed BMs after,
respectively, 24 and 5 months.
Based on these findings, can we consider the presence
BMs always associated with poor prognosis in RCC
patients? Our study aimed to identify existing prognostic
factors affecting the outcome of patients with BMs. We
showed that age ≥ 65 years, ECOG-PS < 2 and clear cell
histology were associated with longer survival. Moreover,
MSKCC risk group and ECOG-PS were independent
prognostic factors at multivariate analysis. These data
are even more interesting if we consider that elderly
RCC patients as well as patients with ECOG-PS > 2 or
non-clear cell histology have been commonly excludedfrom clinical trials on the use of targeted agents or
bisphosphonates, thus hampering the development of
effective therapies for these patients.
We also reported the incidence and prognostic role
of concomitant metastases in patients with BMs. We
showed that lung, lymph node and liver were the most
common sites of concomitant metastases. The pres-
ence of lymph-node and/or lung metastases were in-
dependent prognostic factors in patients with BMs.
Interestingly, the presence of concomitant liver metas-
tases was not an independent prognostic factor in our
population, suggesting that future attempts are re-
quired in order to optimize the management of pa-
tients with concomitant liver and BMs.
We also found that concomitant lung metastases were
more frequent in patients with TTBM < 1, and patients
with TTBM >5 years had significant longer survival than
patients with TTBM < 1 or between 1 and 5 years.
The main limitations of this study include its retrospect-
ive design, which is susceptible to bias in data selection
and analysis and the heterogeneity of standardized
methods used to detect BMs, with each methodology
having its own limit of detection.
Despite these limitations, our study suggests that age,
ECOG-PS, MSKCC score, TTBM and the presence of
concomitant metastases should be necessary considered in
Santoni et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:10 Page 8 of 9order to optimize the prognosis of patients with RCC and
BMs. The understanding of the molecular phenotypes of
BM-initiating cells in RCC could play a fundamental role
in developing therapeutic strategies for these patients.
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